Literature DB >> 19628079

Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma.

Jennifer Sullivan1, Laurel Blair, Amer Alnajar, Tamer Aziz, Chee Yuan Ng, Galina Chipitsyna, Qiaoke Gong, Agnes Witkiewicz, Georg F Weber, David T Denhardt, Charles J Yeo, Hwyda A Arafat.   

Abstract

BACKGROUND: Osteopontin (OPN) is a secreted phosphoprotein that confers on cancer cells a migratory phenotype. We demonstrated recently that nicotine, a major risk factor in pancreatic ductal adenocarcinoma (PDA), increases OPN expression in PDA cells. An OPN splice variant, OPNc, supports anchorage independence and maybe the most potent OPN isoform to convey metastatic behavior. In this study, we tested the effect of nicotine on OPNc expression and analyzed the correlation between total OPN/OPNc levels and patients' smoking history.
METHODS: Real-time polymerase chain reaction and ultraviolet light illumination of ethidium-bromide staining were used to examine the mRNA expression in tissue and in PDA cells treated with or without nicotine (3-300 nmol/L). OPN and OPNc were localized by immunohistochemistry, and an enzyme-linked immunosorbent assay was used to analyze OPN serum levels.
RESULTS: Nicotine treatment of PDA cells selectively induced de novo expression of OPNc. OPNc was found in 87% of invasive PDA lesions, of which 73% were found in smokers. The levels of OPNc correlated well with higher expression levels of total OPN in the tissue and serum from patients with invasive PDA.
CONCLUSION: Our data suggest that smoking and nicotine may contribute to PDA metastatic potential through promoting OPNc expression. Although the direct role of OPNc in PDA progression is not defined, OPNc may have value as a diagnostic and prognostic marker, especially in invasive PDA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19628079      PMCID: PMC2777713          DOI: 10.1016/j.surg.2009.03.036

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  23 in total

1.  An osteopontin splice variant induces anchorage independence in human breast cancer cells.

Authors:  B He; M Mirza; G F Weber
Journal:  Oncogene       Date:  2006-04-06       Impact factor: 9.867

2.  Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.

Authors:  Jens Koopmann; C Nicole White Rosenzweig; Zhen Zhang; Marcia I Canto; David A Brown; Mark Hunter; Charles Yeo; Daniel W Chan; Samuel N Breit; Michael Goggins
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

3.  Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions.

Authors:  A Kolb; J Kleeff; A Guweidhi; I Esposito; N A Giese; H Adwan; T Giese; M W Büchler; M R Berger; H Friess
Journal:  Cancer Biol Ther       Date:  2005-07-05       Impact factor: 4.742

4.  Osteopontin inhibits macrophage nitric oxide synthesis to enhance tumor proliferation.

Authors:  Philip Y Wai; Luci Guo; Chenjiang Gao; Zhiyong Mi; Hongtao Guo; Paul C Kuo
Journal:  Surgery       Date:  2006-08       Impact factor: 3.982

Review 5.  Smoking-gene interaction and disease development: relevance to pancreatic cancer and atherosclerosis.

Authors:  Xing Li Wang; Jian Wang
Journal:  World J Surg       Date:  2005-03       Impact factor: 3.352

6.  Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo.

Authors:  H C Crawford; L M Matrisian; L Liaw
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

7.  Osteopontin expression and distribution in human carcinomas.

Authors:  L F Brown; A Papadopoulos-Sergiou; B Berse; E J Manseau; K Tognazzi; C A Perruzzi; H F Dvorak; D R Senger
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

8.  Induction of pancreatic acinar pathology via inhalation of nicotine.

Authors:  P Chowdhury; P L Rayford; L W Chang
Journal:  Proc Soc Exp Biol Med       Date:  1992-11

Review 9.  Epidemiology and risk factors for pancreatic cancer.

Authors:  Albert B Lowenfels; Patrick Maisonneuve
Journal:  Best Pract Res Clin Gastroenterol       Date:  2006-04       Impact factor: 3.043

10.  Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells.

Authors:  Zhiyong Mi; Hongtao Guo; Philip Y Wai; Chengjiang Gao; Paul C Kuo
Journal:  Carcinogenesis       Date:  2006-02-12       Impact factor: 4.944

View more
  16 in total

1.  Pre- and post-translational regulation of osteopontin in cancer.

Authors:  Pieter H Anborgh; Jennifer C Mutrie; Alan B Tuck; Ann F Chambers
Journal:  J Cell Commun Signal       Date:  2011-04-26       Impact factor: 5.782

2.  Matricellular proteins osteopontin and osteonectin/SPARC in pancreatic carcinoma.

Authors:  Anne M Delany
Journal:  Cancer Biol Ther       Date:  2010-07-01       Impact factor: 4.742

3.  Angiotensin 1-7, but not the thrombin-cleaved osteopontin C-terminal fragment, attenuates osteopontin-mediated macrophage-induced endothelial-cell inflammation.

Authors:  Rachel Hamias; Assaf Rudich; George Greenberg; Gabriel Szendro; Talya Wolak
Journal:  Inflamm Res       Date:  2017-11-27       Impact factor: 4.575

Review 4.  SIBLINGs and SPARC families: their emerging roles in pancreatic cancer.

Authors:  Ferda Kaleağasıoğlu; Martin R Berger
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

5.  Role of IL-6 in the resolution of pancreatitis in obese mice.

Authors:  Maria Pini; Davina H Rhodes; Karla J Castellanos; Andrew R Hall; Robert J Cabay; Rohini Chennuri; Eileen F Grady; Giamila Fantuzzi
Journal:  J Leukoc Biol       Date:  2012-03-16       Impact factor: 4.962

Review 6.  Interplay between smoking-induced genotoxicity and altered signaling in pancreatic carcinogenesis.

Authors:  Navneet Momi; Sukhwinder Kaur; Moorthy P Ponnusamy; Sushil Kumar; Uwe A Wittel; Surinder K Batra
Journal:  Carcinogenesis       Date:  2012-05-23       Impact factor: 4.944

7.  Osteopontin (OPN) isoforms, diabetes, obesity, and cancer; what is one got to do with the other? A new role for OPN.

Authors:  Konrad Sarosiek; Elizabeth Jones; Galina Chipitsyna; Mazhar Al-Zoubi; Christopher Kang; Shivam Saxena; Ankit V Gandhi; Jocelyn Sendiky; Charles J Yeo; Hwyda A Arafat
Journal:  J Gastrointest Surg       Date:  2015-01-13       Impact factor: 3.452

8.  Induction of monocyte chemoattractant protein-1 by nicotine in pancreatic ductal adenocarcinoma cells: role of osteopontin.

Authors:  Melissa Lazar; Jennifer Sullivan; Galina Chipitsyna; Tamer Aziz; Ahmed F Salem; Qiaoke Gong; Agnes Witkiewicz; David T Denhardt; Charles J Yeo; Hwyda A Arafat
Journal:  Surgery       Date:  2010-06-25       Impact factor: 3.982

9.  Osteopontin undergoes polymerization in vivo and gains chemotactic activity for neutrophils mediated by integrin alpha9beta1.

Authors:  Norihisa Nishimichi; Hiromi Hayashita-Kinoh; Chun Chen; Haruo Matsuda; Dean Sheppard; Yasuyuki Yokosaki
Journal:  J Biol Chem       Date:  2011-02-14       Impact factor: 5.157

10.  Osteopontin splice variant as a potential marker for metastatic disease in pancreatic adenocarcinoma.

Authors:  Ali A Siddiqui; Elizabeth Jones; Darren Andrade; Apeksha Shah; Thomas E Kowalski; David E Loren; Galina Chipitsyna; Hwyda A Arafat
Journal:  J Gastroenterol Hepatol       Date:  2014-06       Impact factor: 4.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.